Shares of Regentis Biomaterials Ltd. (RGNT) are surging over 200% to $4.11 after the company announced plans to begin its European surgeon training activities in the third quarter, as it advances preparations for the commercial rollout of GelrinC in Europe.
Regentis is a regenerative medicine company focused on innovative tissue repair solutions.
GelrinC is Regentis' cell-free off-the-shelf hydrogel implant having synchronised erosion and resorption for the treatment of knee cartilage lesions, which is estimated by the company to be a $3 billion U.S. market.
Notably, GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal study in the US that has completed over 50% of enrollment.
The training program is designed to teach orthopaedic surgeons to use GelrinC and provide practical experience with the implantation procedure. This may support physician readiness ahead of market launch.
In addition, as part of its European strategy, Regentis is establishing a network of European Centres of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing on cartilage repair and the use of GelrinC.
The first training activities are expected to take place in Milan, Italy, at Humanitas Research Hospital, an academic medical centre in orthopaedics and sports medicine.
RGNT has traded between $1.23 and $8.35 over the last year. The stock closed Monday's trade at $1.29.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.